Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Mudcat who wrote (28992)	6/28/1999 10:50:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

I was talking about projections made in 1998, not 1996 or 1997. In 1996 and 1997, LGND wasn't talking about acquiring SRGN or filing an ONTAK application, which they did and got the drug approved. In 1996, they were talking about the Targretin drugs being the 2nd and 3rd FDA approvals. Now they are talking about them being the 3rd and 4th approvals. In 1998 they were initially talking about late 1998, early 1999 for oral Targretin, and then nailed the time down to 1H, 1999, a target date that was met.